A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 8, 2009

Abbott Wins Appeal on Norvir Antitrust Case

A federal appellate court has ruled in favor of Abbott Laboratories and dismissed claims that the company is guilty of maintaining a monopoly in the HIV treatment marketplace and overcharging for its protease inhibitor Norvir (ritonavir).

In 2003, Abbott raised the price of Norvir by 400 percent. Because most other protease inhibitors require a low-dose of Norvir to boost their blood levels and render them more effective and/or easier to take, this meant that the overall cost of treatment with those drugs increased dramatically. Though Abbott hiked up the price of Norvir, it failed to do the same for its own combination pill, Kaletra, which includes low-dose Norvir and another protease inhibitor lopinavir.

The Service Employees International Union Health and Welfare Fund, a plaintiff in the law suit, argued that raising the price of Norvir, but not Kaletra, amounted to maintaining a monopoly in the protease inhibitor market. The union had previously settled with Abbott after a suit in a lower court. That settlement involved a $10 million payment to nonprofit groups that help people with HIV, with additional payments of $17.5 million if the appellate court upheld the lower court’s decision. However, according to an opinion filed July 7 by U.S. Court of Appeals for the Ninth Circuit by judges Mary Schroeder, Stephen Reinhardt and Pamela Ann Rymer, no violation of antitrust statutes was evident.  

The union said that the ruling doesn’t affect the original $10 million payment. Additional suits against Abbott over the Norvir price increase are still pending in other jurisdictions.

Search: Abbott, court case, appeal, antitrust, Service Employees International Union, SEIU, Norvir, ritonavir, protease inhibitors


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    charliehunter
    San Francisco
    California


    juliar33
    brooklyn
    New York


    ernienyc
    Bronx
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.